MGLN insider filings
MAGELLAN HEALTH INC — 45 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-01-04. Screen MGLN transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for MGLN between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — MAGELLAN HEALTH INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-01-04 | 4 | Bourdon David — Chief Financial Officer | Disposition to issuer (D): 1,330 · Disposition to issuer (D): 4,383 (derivative) · Disposition to issuer (D): 16,963 (derivative) · Disposition to issuer (D): 4,362 (derivative) | EDGAR |
| 2022-01-04 | 4 | Chen Christopher J — Director | Disposition to issuer (D): 2,911 @ $0 | EDGAR |
| 2022-01-04 | 4 | Abbott Swati Bargotra — Director | Disposition to issuer (D): 6,847 @ $0 | EDGAR |
| 2022-01-04 | 4 | Kamal Mostafa — CEO, Magellan Rx Management | Disposition to issuer (D): 5,994 · Disposition to issuer (D): 27,205 (derivative) · Disposition to issuer (D): 24,748 (derivative) · Disposition to issuer (D): 12,482 (derivative) · Disposition to issuer (D): 25,439 (derivative) · Disposition to issuer (D): 10,679 (derivative) · +1 more | EDGAR |
| 2022-01-04 | 4 | Norwalk Leslie V — Director | Disposition to issuer (D): 5,698 @ $0 | EDGAR |
| 2022-01-04 | 4 | Haddock David — General Counsel & Secretary | Disposition to issuer (D): 2,961 · Disposition to issuer (D): 8,473 (derivative) · Disposition to issuer (D): 11,309 (derivative) · Disposition to issuer (D): 10,605 (derivative) | EDGAR |
| 2022-01-04 | 4 | Lewis Clapper Caskie — Chief Human Resources Officer | Disposition to issuer (D): 19,510 · Disposition to issuer (D): 20,281 (derivative) · Disposition to issuer (D): 14,057 (derivative) · Disposition to issuer (D): 12,949 (derivative) · Disposition to issuer (D): 12,330 (derivative) · Disposition to issuer (D): 30,843 (derivative) · +4 more | EDGAR |
| 2022-01-04 | 4 | Feld Peter A — Director | Disposition to issuer (D): 5,698 · Disposition to issuer (D): 1,419,053 · Disposition to issuer (D): 228,603 · Disposition to issuer (D): 130,301 · Disposition to issuer (D): 85,229 · Disposition to issuer (D): 200,300 · +1 more | EDGAR |
| 2022-01-04 | 4 | MACKENZIE GREGORY SCOTT — Director | Disposition to issuer (D): 10,594 @ $0 | EDGAR |
| 2022-01-04 | 4 | SANSONE GUY P — Director | Disposition to issuer (D): 7,973 @ $0 | EDGAR |
| 2022-01-04 | 4 | SHULMAN STEVEN J — Director | Disposition to issuer (D): 27,451 @ $0 | EDGAR |
| 2022-01-04 | 4 | WEST JEFFREY N — SVP & Controller | Disposition to issuer (D): 25,692 · Disposition to issuer (D): 2,365 (derivative) · Disposition to issuer (D): 3,404 (derivative) · Disposition to issuer (D): 4,808 (derivative) · Disposition to issuer (D): 3,538 (derivative) · Disposition to issuer (D): 1,447 (derivative) · +2 more | EDGAR |
| 2022-01-04 | 4 | JOSEPHSON MURAL R — Director | Disposition to issuer (D): 2,911 @ $0 | EDGAR |
| 2022-01-04 | 4 | FASOLA KENNETH J — Chief Executive Officer, Director | Disposition to issuer (D): 17,141 · Disposition to issuer (D): 8,580 (derivative) · Disposition to issuer (D): 22,196 (derivative) · Disposition to issuer (D): 43,080 (derivative) · Disposition to issuer (D): 18,411 (derivative) · Disposition to issuer (D): 27,743 (derivative) | EDGAR |
| 2022-01-04 | 4 | MURRAY JAMES E — President and COO | Option exercise (M): 3,262 · Tax withholding (F): 871 @ $94.99 · Disposition to issuer (D): 13,203 · Option exercise (M): 3,262 (derivative) · Disposition to issuer (D): 25,346 (derivative) · Disposition to issuer (D): 3,262 (derivative) · +4 more | EDGAR |
| 2021-12-06 | 4 | FASOLA KENNETH J — Chief Executive Officer, Director | Option exercise (M): 8,580 @ $0 · Tax withholding (F): 3,376 @ $94.62 · Option exercise (M): 8,580 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | Bourdon David — Chief Financial Officer | Option exercise (M): 2,192 @ $0 · Tax withholding (F): 862 @ $94.68 · Option exercise (M): 2,192 (derivative) @ $0 | EDGAR |
| 2021-08-17 | 4 | Feld Peter A — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-08-13 | 4 | Chen Christopher J — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-08-13 | 4 | Abbott Swati Bargotra — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-08-13 | 4 | Norwalk Leslie V — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-08-13 | 4 | MACKENZIE GREGORY SCOTT — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-08-13 | 4 | SANSONE GUY P — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-08-13 | 4 | SHULMAN STEVEN J — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-08-13 | 4 | JOSEPHSON MURAL R — Director | Grant/award (A): 789 @ $0 | EDGAR |
| 2021-03-08 | 4 | WEST JEFFREY N — SVP & Controller | Option exercise (M): 839 @ $0 · Option exercise (M): 1,447 @ $0 · Tax withholding (F): 677 @ $93.29 · Option exercise (M): 839 (derivative) @ $0 · Option exercise (M): 1,447 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | Bourdon David — Chief Financial Officer | Grant/award (A): 16,963 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | Kamal Mostafa — CEO, Magellan Rx Management | Option exercise (M): 6,242 @ $0 · Tax withholding (F): 3,072 @ $93.47 · Grant/award (A): 25,439 (derivative) @ $0 · Option exercise (M): 6,242 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | Lewis Clapper Caskie — Chief Human Resources Officer | Option exercise (M): 2,435 @ $0 · Tax withholding (F): 1,109 @ $93.47 · Grant/award (A): 9,733 (derivative) @ $0 · Option exercise (M): 2,435 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | WEST JEFFREY N — SVP & Controller | Option exercise (M): 1,769 @ $0 · Tax withholding (F): 562 @ $93.47 · Grant/award (A): 4,808 (derivative) @ $0 · Option exercise (M): 1,769 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | FASOLA KENNETH J — Chief Executive Officer, Director | Option exercise (M): 11,099 @ $0 · Tax withholding (F): 4,366 @ $93.47 · Grant/award (A): 43,080 (derivative) @ $0 · Option exercise (M): 11,099 (derivative) @ $0 | EDGAR |
| 2021-03-05 | 4 | MURRAY JAMES E — President and COO | Option exercise (M): 7,284 @ $0 · Tax withholding (F): 2,866 @ $93.47 · Grant/award (A): 28,271 (derivative) @ $0 · Option exercise (M): 7,284 (derivative) @ $0 | EDGAR |
| 2021-03-04 | 4 | Haddock David — General Counsel & Secretary | Option exercise (M): 4,237 @ $0 · Tax withholding (F): 1,276 @ $93 · Option exercise (M): 4,237 (derivative) @ $0 · Grant/award (A): 11,309 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | MURRAY JAMES E — President and COO | Option exercise (M): 3,262 @ $0 · Tax withholding (F): 1,368 @ $82.84 · Option exercise (M): 3,262 (derivative) @ $0 | EDGAR |
| 2020-12-11 | 4 | Kamal Mostafa — CEO, Magellan Rx Management | Sale (S): 2,793 @ $79.69 | EDGAR |
| 2020-12-04 | 4 | FASOLA KENNETH J — Chief Executive Officer, Director | Option exercise (M): 8,580 @ $0 · Tax withholding (F): 3,376 @ $78.55 · Option exercise (M): 8,580 (derivative) @ $0 | EDGAR |
| 2020-11-17 | 4 | Kamal Mostafa — CEO, Magellan Rx Management | Option exercise/expiry (X): 13,282 @ $68.50 · Sale (S): 13,282 @ $83.82 · Option exercise/expiry (X): 7,603 @ $66.57 · Sale (S): 7,603 @ $86.57 · Option exercise/expiry (X): 13,282 (derivative) @ $0 · Option exercise/expiry (X): 7,603 (derivative) @ $0 | EDGAR |
| 2020-11-12 | 4 | Kamal Mostafa — CEO, Magellan Rx Management | Option exercise/expiry (X): 6,000 @ $66.57 · Sale (S): 6,000 @ $81.57 · Option exercise/expiry (X): 6,000 (derivative) @ $0 | EDGAR |
| 2020-11-06 | 4 | Kamal Mostafa — CEO, Magellan Rx Management | Option exercise/expiry (X): 3,434 @ $64.87 · Sale (S): 3,434 @ $79.89 · Option exercise/expiry (X): 3,589 @ $64.87 · Sale (S): 3,589 @ $79.87 · Option exercise/expiry (X): 3,434 (derivative) @ $0 · Option exercise/expiry (X): 3,589 (derivative) @ $0 | EDGAR |
| 2020-11-06 | 4 | WEST JEFFREY N — SVP & Controller | Option exercise/expiry (X): 1,298 @ $68.50 · Option exercise/expiry (X): 1,183 @ $66.57 · Sale (S): 2,481 @ $80.00 · Sale (S): 139 @ $80.00 · Option exercise/expiry (X): 1,298 (derivative) @ $0 · Option exercise/expiry (X): 1,183 (derivative) @ $0 | EDGAR |
| 2020-10-20 | 4 | Kamal Mostafa — CEO, Magellan Rx Management | Option exercise/expiry (X): 183 @ $64.87 · Sale (S): 183 @ $79.87 · Option exercise/expiry (X): 183 (derivative) @ $0 | EDGAR |
| 2020-10-14 | 4 | WEST JEFFREY N — SVP & Controller | Option exercise/expiry (X): 8,890 @ $60.39 · Option exercise/expiry (X): 8,890 @ $78.53 · Option exercise/expiry (X): 8,890 (derivative) @ $0 | EDGAR |
| 2020-10-09 | 4/A | Bourdon David — Chief Financial Officer | Grant/award (A): 6,575 (derivative) @ $0 · Grant/award (A): 4,362 (derivative) @ $0 | EDGAR |
| 2020-10-07 | 4 | WEST JEFFREY N — SVP & Controller | Option exercise/expiry (X): 10,437 @ $63.95 · Option exercise/expiry (X): 4,200 @ $60.39 · Sale (S): 14,637 @ $78.51 · Option exercise/expiry (X): 4,778 @ $60.39 · Sale (S): 4,778 @ $78.50 · Option exercise/expiry (X): 1,500 @ $60.39 · +5 more | EDGAR |
| 2020-10-05 | 4 | Bourdon David — Chief Financial Officer | Grant/award (A): 6,598 (derivative) @ $0 · Grant/award (A): 4,362 (derivative) @ $0 | EDGAR |
Recent 8-K events — MAGELLAN HEALTH INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-01-04 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-12-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-03-31 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2021-03-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2021-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-01-06 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-01-04 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MGLN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs